U.S. Retail Distributors Stock News

Helen of Troy Limited ( NASDAQ:HELE ), might not be a large cap stock, but it received a lot of attention from a...

Earlier in 2026, Revolution Medicines reported Phase 3 data showing its RAS(ON) inhibitor daraxonrasib delivered a statistically significant survival benefit in advanced pancreatic cancer, supporting an ongoing New Drug Application process and expanded access program in the US. Beyond this single trial, the readout effectively confirms RAS(ON) inhibition as a clinically validated approach in a high‑mortality tumor, with implications for the company’s broader RAS-focused pipeline and its...

Ligand Pharmaceuticals (LGND) has drawn fresh attention after recent trading, with the stock last closing at US$253.25. For investors, the focus now is on how this biopharmaceutical licensing model aligns with their portfolio goals. See our latest analysis for Ligand Pharmaceuticals. The recent 1 day share price decline of 0.90% to US$253.25 comes after a strong run, with a 30 day share price return of 18.78% and a 1 year total shareholder return of 120.20%, suggesting momentum has been...

If you are wondering whether Datadog stock is offering value at current levels, it helps to separate the recent share price excitement from what the fundamentals might support. Datadog last closed at US$233.09, with returns of 0.6% over 7 days, 12.1% over 30 days, 74.2% year to date, 91.2% over 1 year, 143.4% over 3 years and 127.7% over 5 years. These figures naturally raise questions about what is already reflected in the price. Recent coverage around Datadog has focused on its role in...

Earlier in June 2026, Viasat announced it had been awarded a prime contract by the U.S. Space Force to build, launch and operate the first small, maneuverable geosynchronous satellite under the Protected Tactical SATCOM‑Global program, including ground systems and five years of operations support. This Swarm 1 Delivery Order advances Viasat’s role in secure, anti‑jam military communications and could deepen its position as a key supplier of resilient GEO satellite infrastructure to the U.S...

Muted stock reaction to new battery order Enovix (ENVX) recently announced a new battery order, but the stock reaction has been muted as investors weigh ongoing concerns about sustained demand and slow progress in drone battery applications over recent quarters. See our latest analysis for Enovix. Against this muted reaction to the new order, Enovix’s recent share price performance has been mixed, with a 46.28% 90 day share price return but a year to date share price decline of 10.27% and a 1...

Earlier this week, the Trump administration announced a peace deal enabling the reopening of the Strait of Hormuz, which pushed long-term Treasury yields lower and improved the backdrop for rate‑sensitive assets such as high-growth software companies. This shift in bond markets matters for MongoDB because lower discount rates can increase the present value investors assign to its expected future cash flows, especially given its growth-focused business model. We’ll now examine how the drop in...

Humana (HUM) has drawn fresh attention after recent trading, with the stock showing a mix of short term gains and longer term declines that raises questions about how investors currently view its valuation. See our latest analysis for Humana. Recent trading has pushed Humana’s share price to $380.26, with a 30 day share price return of 24.63% and a 1 year total shareholder return of 64.10%. However, 3 and 5 year total shareholder returns remain in decline, suggesting momentum has recently...

Recent analysis of StoneX Group highlights strong past revenue and earnings per share growth, underlining the company’s expanding presence across its global financial services network. Commentary also points to balance sheet strength and rising tangible book value per share, reinforcing confidence in the durability of StoneX’s business model. We’ll now examine how this emphasis on earnings and tangible book value growth shapes StoneX Group’s broader investment narrative. We've uncovered the...

First Industrial Realty Trust (FR) drew fresh attention after reporting quarterly earnings and revenue that exceeded expectations, supported by healthy leasing activity, rental growth, and demand for its logistics and warehouse focused industrial portfolio. See our latest analysis for First Industrial Realty Trust. Against this earnings backdrop, First Industrial Realty Trust’s share price has moved steadily higher, with a year to date share price return of 9.45% and a 1 year total...

Earlier in June 2026, REX American Resources filed a US$69.00 million shelf registration for 1,500,000 common shares tied to an ESOP-related offering, while also reporting record Q1 2026 earnings per share of US$0.56 that exceeded expectations despite softer revenue. The board’s approval of a new Restricted Stock Unit Award Agreement under the 2026 Incentive Plan highlights an increased focus on equity-based compensation to align employees with long-term corporate objectives. Next, we’ll...

Five Below (FIVE) has drawn fresh attention after reporting first quarter results, updating guidance for 2026, and benefiting from viral Cardi B social media posts that spotlighted the retailer to a wider audience. See our latest analysis for Five Below. Five Below’s share price has been choppy in recent months, with a 7 day share price return of 3.98% but a 30 day share price return that is down 9.23%, while the 1 year total shareholder return of 53.33% points to stronger longer term...

Why recent analyst attention is putting Pitney Bowes stock on more radar screens Recent analyst coverage citing strong buy ratings, higher dividend yield, and growth efforts in shipping software has pushed Pitney Bowes (PBI) into sharper focus for income oriented and value focused investors. See our latest analysis for Pitney Bowes. The recent analyst enthusiasm comes after a strong run in Pitney Bowes' share price, with a 90 day share price return of 66.25% and a 1 year total shareholder...

GitLab (GTLB) stock is back in focus after the company expanded its Google Cloud collaboration by adding Gemini and Gemma AI models to GitLab Duo and launching a managed, compliance focused DevSecOps offering for enterprises. See our latest analysis for GitLab. Recent GitLab earnings, product launches at GitLab Transcend, and the expanded Google Cloud partnership have arrived alongside mixed performance, with a 30 day share price return of 19.65% and a 1 year total shareholder return that...

Charles Schwab (SCHW) is back in focus after its May activity report showed record net new assets, total client assets above $13.1b, and a sharp pickup in new brokerage accounts. See our latest analysis for Charles Schwab. After the strong May activity update and new trading features such as 24/7 cryptocurrency futures and expanded fractional trading, Charles Schwab’s share price has cooled this year, with the year to date share price return down 10.46%, even as the 3 year total shareholder...

Xylem Inc. recently announced a landmark agreement with Dow Inc. to design, build and operate an advanced, site-wide water treatment and reuse system at Dow’s large industrial complex in Fort Saskatchewan, Alberta, with operations targeted to begin by August 2028. The deal makes Xylem responsible for the full water cycle, from raw water treatment to converting processed water into reusable supply, showcasing how integrated reuse can cut freshwater demand and support more resilient industrial...

Axsome Therapeutics presented new Phase 3 data on AXS-12 in narcolepsy at a major sleep medicine conference. The company also shared Phase 3 and post hoc analyses on solriamfetol related to sleep disorders such as sleep apnea. These presentations focus on central nervous system conditions and add fresh clinical detail to Axsome Therapeutics' late stage pipeline. Axsome Therapeutics (NasdaqGM:AXSM) is drawing attention after releasing new Phase 3 and post hoc data on AXS-12 and solriamfetol...

How Reddit’s recent stock moves frame the valuation question If you are trying to work out whether Reddit stock is priced attractively or already baking in big expectations, the recent share performance and valuation checks offer some useful clues. Reddit closed at US$181.88, with returns of 6.3% over the past 7 days, 15.0% over the past 30 days, a year to date decline of 24.8%, and a 44.1% gain over the last year. Recent coverage has focused on Reddit’s position as a social platform with...

If you are wondering whether LiveRamp Holdings stock still offers value at its current price, the key is understanding what the recent share performance says about expectations built into the valuation. The stock last closed at US$37.57, with returns of 0.2% over 7 days, 26.7% over 30 days, 37.0% year to date, 18.4% over 1 year, 44.4% over 3 years, and a decline of 10.5% over 5 years, which gives mixed signals about how the market has priced the company over different time frames. Recent...

Artificial intelligence is no longer just a buzzword; it is a core part of how chips, software, cloud platforms and tools like ChatGPT are being built and used. With inflation pressures easing in some regions and central banks reassessing policy, investors are again paying attention to companies directly tied to this shift, from semiconductors to large language models. The AI Stocks screener focuses on businesses at the heart of that transition, helping you filter a crowded market into a more...

Prestige Consumer Healthcare (PBH) is back in focus after fiscal 2026 earnings missed estimates, revenue declined year over year, and guidance for fiscal 2027 came in below consensus expectations. See our latest analysis for Prestige Consumer Healthcare. Those weaker fiscal 2026 results, cautious fiscal 2027 guidance, and the new investor investigation have coincided with a sharp loss of momentum, with Prestige Consumer Healthcare’s share price down 25.1% over 90 days and its 1 year total...

Fiserv (NasdaqGS:FISV) has announced an abrupt CEO transition, with Takis Georgakopoulos appointed to replace Mike Lyons. Lyons is leaving the company after just over a year in the role to join Truist Financial. The leadership change follows sustained pressure from activist investor Jana Partners and comes during major operational and portfolio shifts. Fiserv is making this leadership change while its share price stands at $47.91 and longer term returns have been weak, with the stock down...

Outlook Therapeutics previously secured FDA acceptance of its resubmitted Biologics License Application for ONS-5010/Lytenava, following a successful appeal that confirmed substantial evidence of effectiveness and removed the requirement for new clinical trials. The FDA’s Class 1 review with a roughly 60-day PDUFA timeline, combined with ongoing launches in Europe and the UK, places Lytenava at the center of Outlook Therapeutics’ path toward broader commercial reach. We’ll now examine how...

Williams-Sonoma (NYSE:WSM) has launched the GreenRow x NYBG home collection in collaboration with the New York Botanical Garden. The collection features sustainable home textiles and décor inspired by botanical artwork from NYBG’s historical archives. The partnership supports NYBG’s plant science mission while expanding Williams-Sonoma’s presence in environmentally focused home design. For investors tracking Williams-Sonoma, the GreenRow x NYBG launch adds context to a stock that has seen...